XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Divestitures
3 Months Ended
Aug. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Divestitures
2. DIVESTITURES
Pursuant to an asset purchase agreement dated June 8, 2023 (the "Asset Purchase Agreement"), the Company completed the sale of the dialysis and BioSentry tract sealant system biopsy businesses (the "Divestiture") to Merit Medical Systems, Inc. ("Merit"). Total consideration received by the Company for the Divestiture in the first quarter of fiscal year 2024 was $100.0 million in cash and resulted in a pre-tax book gain of $47.8 million.
The Company and Merit entered into various agreements to facilitate the transition of the divested businesses to Merit, including a Transition Services Agreement and Contract Manufacturing Agreement. The Company determined that the sale of the businesses did not constitute a strategic shift that had a major effect on the Company's operations or financial results and as a result, this transaction will not be classified as discontinued operations.
The following table summarizes the major classes of assets sold on the date of the sale:
(in thousands)As of June 8, 2023
Current assets:
Inventories $4,068 
Prepaid expenses and other2,000 
   Total current assets$6,068 
Non-current assets:
Property, plant and equipment, net$54 
Intangible assets, net17,629 
Goodwill25,980 
   Total non-current assets $43,663